Precigen, Inc. Long-Term Investments

Long-Term Investments of PGEN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Long-Term Investments growth rates and interactive chart. An accounting item that represents the company's investments, including stocks, bonds, real estate, and cash. Long-term investments are assets that a company intends to hold for more than a year. The long-term investment account differs largely from the short-term investment account in that short-term investments will most likely be sold, whereas the long-term investments will not be sold for years and, in some cases, may never be sold.

Highlights and Quick Summary

  • Long-Term Investments for the quarter ending September 29, 2021 was $67.4 Million (a -21.41% decrease compared to previous quarter)
  • Year-over-year quarterly Long-Term Investments increased by 14606.99%
  • Annual Long-Term Investments for 2020 was $458 Thousand (a -75.63% decrease from previous year)
  • Annual Long-Term Investments for 2019 was $1.88 Million (a -44.69% decrease from previous year)
  • Annual Long-Term Investments for 2018 was $3.4 Million (a -98.22% decrease from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Long-Term Investments of Precigen, Inc.

Most recent Long-Term Investmentsof PGEN including historical data for past 10 years.

Interactive Chart of Long-Term Investments of Precigen, Inc.

Precigen, Inc. Long-Term Investments for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $67.36 $85.71 $103.61
2020 $0.46 $0.77 $0.86 $1.11 $0.46
2019 $1.46 $24.0 $39.6 $19.23 $1.88
2018 $2.78 $180.35 $183.83 $198.22 $3.4
2017 $189.91 $198.08 $190.55 $180.09 $190.4
2016 $182.72 $233.08 $232.2 $158.29 $183.21
2015 $199.08 $216.68 $104.86 $307.0 $199.08
2014 $195.22 $153.34 $213.44 $214.63 $195.22
2013 $208.39 $193.68 $65.21 $208.39
2012 $88.84
2011 $39.09 $39.1

Business Profile of Precigen, Inc.

Sector: Healthcare
Industry: Biotechnology
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Fibrocell Science, Inc.; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Holdings, Inc. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.